6-oxo-4-phenyl-1H-pyrimidine-2-carboxylic acid | 1056628-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-oxo-4-phenyl-1H-pyrimidine-2-carboxylic acid
• CAS: 1056628-89-7
• 化学式: C₁₁H₈N₂O₃
• 分子量: 216.196
• InChiKey: SFKZPPXTYLQSSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-oxo-4-phenyl-1H-pyrimidine-2-carboxylic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation

  摘要：

  Piperazinyl-glutamate-pyrimidines were prepared with oxygen, nitrogen, and sulfur substitution at the 4-position of the pyrimidine leading to highly potent P2Y(12) antagonists. In particular, 4-substituted piperidine-4-pyrimidines provided compounds with exceptional potency. Pharmacokinetic and physicochemical properties were fine-tuned through modi. cations at the 4-position of the piperidine ring leading to compounds with good human PRP potency, selectivity, clearance and oral bioavailability. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.017
• 作为产物：
  描述：

  ethyl 4-hydroxy-6-phenylpyrimidine-2-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 6-oxo-4-phenyl-1H-pyrimidine-2-carboxylic acid
  参考文献：
  名称：

  Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation

  摘要：

  Piperazinyl-glutamate-pyrimidines were prepared with oxygen, nitrogen, and sulfur substitution at the 4-position of the pyrimidine leading to highly potent P2Y(12) antagonists. In particular, 4-substituted piperidine-4-pyrimidines provided compounds with exceptional potency. Pharmacokinetic and physicochemical properties were fine-tuned through modi. cations at the 4-position of the piperidine ring leading to compounds with good human PRP potency, selectivity, clearance and oral bioavailability. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.017

文献信息

• Metalloprotease inhibitors containing a squaramide moiety
  申请人：Gege Christian

  公开号：US20080221128A1

  公开（公告）日：2008-09-11

  The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Metalloprotease inhibitors containing a heterocyclic moiety
  申请人：Gege Christian

  公开号：US20080221095A1

  公开（公告）日：2008-09-11

  The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• [EN] METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASE CONTENANT UNE FRACTION SQUARAMIDE
  申请人：ALANTOS PHARM HOLDING

  公开号：WO2008109178A1

  公开（公告）日：2008-09-12

  [EN] The present invention relates generally to pharmaceutical agents of Formula (I) containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP 3, MMP 8 and/or MMP 13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP 13, MMP 8 and MMP 3 inhibitors. Formula (I).
  [FR] De manière générale, l'invention concerne des agents pharmaceutiques représentés par la formule (I) qui contiennent une fraction hétérocyclique, et en particulier, des composés inhibiteurs de métalloprotéase hétérocycliques. Plus particulièrement, la présente invention fournit une nouvelle catégorie de composés inhibiteurs de MMP 3, de MMP 8 et/ou de MMP 13 hétérocycliques pourvus d'une fraction squaramide ou benzoxazinone, qui présentent une efficacité et une sélectivité accrues par rapport aux inhibiteurs de MMP 13, de MMP 8 et de MMP 3 actuellement connus. Formule (I)
• [EN] METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASES CONTENANT UNE FRACTION HÉTÉROCYCLIQUE
  申请人：ALANTOS PHARMACEUTICALS HOLDING

  公开号：WO2008109181A2

  公开（公告）日：2008-09-12

  [EN] The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP 3, MMP 8 and/or MMP 13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP 13, MMP 8 and MMP 3 inhibitors.
  [FR] La présente invention porte de manière générale sur des agents pharmaceutiques contenant une fraction hétérocyclique et, en particulier, sur des composés hétérocycliques inhibiteurs de métalloprotéases. Plus particulièrement, la présente invention propose une nouvelle catégorie de composés hétérocycliques inhibiteurs de MMP 3, de MMP 8 et/ou de MMP 13 avec une fraction de squaramide ou de benzoxazinone, qui présentent une efficacité et une sélectivité accrues par rapport aux inhibiteurs de MMP 13, de MMP 8 et de MMP 3 actuellement connus.
• Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation
  作者：John J. Parlow、Mary W. Burney、Brenda L. Case、Thomas J. Girard、Kerri A. Hall、Ronald R. Hiebsch、Rita M. Huff、Rhonda M. Lachance、Deborah A. Mischke、Stephen R. Rapp、Rhonda S. Woerndle、Michael D. Ennis

  DOI：10.1016/j.bmcl.2009.09.017

  日期：2009.11

  Piperazinyl-glutamate-pyrimidines were prepared with oxygen, nitrogen, and sulfur substitution at the 4-position of the pyrimidine leading to highly potent P2Y(12) antagonists. In particular, 4-substituted piperidine-4-pyrimidines provided compounds with exceptional potency. Pharmacokinetic and physicochemical properties were fine-tuned through modi. cations at the 4-position of the piperidine ring leading to compounds with good human PRP potency, selectivity, clearance and oral bioavailability. (c) 2009 Elsevier Ltd. All rights reserved.